South San Francisco, CA, Nov. 14, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine, marked a historic ...

The Application Review Subcommittee (ARS) reviews the Grants Working Group’s and Facilities Working Group’s recommendations for funding and makes decisions on applications for funding in public ...

have the ability to divide and create an identical copy of themselves, a process called self-renewal; and can also divide to form cells that mature into cells that make up every type of tissue and ...

Therapeutic Translational Research Projects University of California, Los Angeles COVID-19 Antiviral Therapy to Block Direct Cell Injury and Associated Tissue Damage $349,999 Quest – Discovery Stage ...

Stem cells have the potential to treat a wide range of diseases. Here, discover why these cells are such a powerful tool for treating disease and what hurdles experts face before new therapies reach ...

What is the California Institute for Regenerative Medicine (CIRM)? CIRM, California’s Stem Cell Agency, was created by the voters of California in 2004 when they overwhelmingly passed Proposition 71, ...

There is no shortage of myths and misconceptions when it comes to stem cell research and regenerative medicine. Here we address the most common concerns. If you have more questions that aren’t ...

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...

The Induced Pluripotent Stem Cell (iPSC) Repository is a major effort from CIRM to create a collection of stem cells developed from thousands of individuals. CIRM is creating the iPSC bank so that ...

The Alpha Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. Browse the list of ongoing trials at ...

Cell and gene therapies face many headwinds: complex preclinical development, constrained GMP manufacturing capacity, limited qualified clinical trial sites, an evolving regulatory landscape and an ...